Equity Overview
Price & Market Data
Price: $19.00
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $33,671,780
Daily Volume: 0
Performance Metrics
1 Week: 2.43%
1 Month: -20.77%
3 Months: -4.47%
6 Months: 142.0%
1 Year: -14.24%
YTD: 23.54%
Company Details
Employees: 29
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.